Ascendiant Capital Maintains Buy on Surgepays, Raises Price Target to $3.75
Ascendiant Capital analyst Edward Woo maintains Surgepays (NASDAQ:SURG) with a Buy and raises the price target from $3.5 to $3.75.
Share
Why It Matters
An analyst who studies stocks thinks Surgepays is a good buy. They raised their price target from $3.50 to $3.75.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.